Dermatology Products · LP-099
Mupirocin Ointment
Generic medicine development record. Review the proposed presentation and the professional reference information below.
Development record
- Portfolio reference
- LP-099Dermatology Products
- Generic identity
- MupirocinOintment
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Ingredient reference
Record identity and reference background.
- Portfolio reference
- LP-099
- Generic ingredient
- Mupirocin
- Dosage form
- Ointment
- Proposed strength
- 2%
- Proposed pack
- Tube 5 g / 15 g
- Portfolio category
- Dermatology Products
About Mupirocin
Mupirocin is an antibiotic ingredient used in topical products for certain susceptible bacterial infections. A skin ointment is a local treatment and is different from a formulation authorized for use in the nose. Its use should follow assessment of the infection and relevant antimicrobial guidance. The term topical does not make all anatomical sites or all mupirocin products interchangeable.
How to read this profile
Scientific information relates to the ingredient and dosage-form context. It is not approved Luang Pharma labelling, a clinical recommendation, or evidence of equivalence to a referenced product. Multiple strengths or presentations represent separate proposed variants and must not be treated as interchangeable.
02 · Professional background
Scientific & clinical reference
Read the clinical context, selected safety considerations and presentation-specific information below.
Clinical context and therapeutic role
Healthcare professionals assess whether a lesion is a limited superficial bacterial infection or requires drainage, a systemic antibiotic or another diagnosis. Selection should consider local resistance and previous treatment. Nasal decolonization protocols require an appropriate nasal formulation and a defined clinical indication; they cannot be inferred from this skin-ointment entry. Persistent, recurrent or spreading symptoms should prompt review rather than repeated unsupported courses.
Important safety considerations
Burning, stinging, itching and local irritation can occur. Severe allergy requires immediate medical help. Do not place a skin ointment in eyes or use it on mucosal surfaces without specific authorization. Some ointment vehicles contain ingredients that require extra caution on extensive damaged skin or in kidney impairment; the exact excipients of this candidate have not been confirmed. Unnecessary or extended use can select less susceptible organisms.
These are selected considerations, not a complete list. Use the current instructions or approved label for the exact authorised product and seek appropriate professional advice.
Presentation, handling and storage
The catalogue specifies an ointment with small tube presentations. The exact base, approved application sites and single-patient instructions require product-specific confirmation. A mupirocin cream or nasal ointment should not be substituted solely because the active ingredient is the same.
Keep the medicine in the labelled original pack with its leaflet. Check the expiry date and pack integrity before dispensing. The authorized label must determine storage temperature, protection from moisture or light, and disposal; no shelf life or in-use period can be established from a catalogue entry.
Final composition, instructions, shelf life and storage conditions are not established by this portfolio entry. They must come from the controlled documentation for the specific product.
Points for professional review
Review the site, likely organism, severity, prior antibiotic exposure and need for culture. Confirm the formulation and approved label before supply for any decolonization or wound-care protocol.
03 · Product enquiry
Documentation & regulatory status
Evidence status
What is established — and what remains open
This record has received an editorial evidence-layer review. The review separates catalogue facts from unresolved product-specific fields and external context; it is not medical, regulatory or market-authorisation approval.
Layer 01
Controlled catalogue facts
- Generic ingredient
- Mupirocin
- Dosage form / presentation
- Ointment
- Catalogue strength
- 2%
- Catalogue pack
- Tube 5 g / 15 g
- Portfolio category
- Dermatology Products
Layer 02
Unresolved product-specific fields
- Exact vehicle/excipient system, intended application site and formulation-specific instructions require controlled product documentation.
- Approved indication, patient eligibility and dosing are not established by this portfolio record.
- Registration, manufacturing/site status, supply availability, storage conditions and shelf life remain product- and market-specific evidence items.
Layer 03
Attributed external context
- MedlinePlus: Mupirocin — ingredient/formulation referencegovernment-hosted medicine monograph
These references provide scientific or regulatory context only. They are not Luang Pharma product labelling, registration, manufacturing evidence, equivalence evidence or confirmation of supply.
Layer 04
Documents required to close the record
- Controlled product master/specification confirming the exact ingredient identity, dosage form, strength variant and pack mapping.
- Destination-market authorisation or other lawful supply-route evidence plus the approved label/leaflet/IFU, where applicable.
- Product-specific composition/excipient, storage, shelf-life and pack-control documentation.
- Manufacturing-site and supply-status evidence before any public claim of installed capability, registration, availability or equivalence.
For LP-099, identify the destination country, intended professional use, proposed presentation and the role of your organisation. The appropriate supply route and available documentation must be confirmed for that case.
- Confirm the legal entity, manufacturing site and authorised scope for the proposed supply chain.
- Confirm product registration or another lawful route, approved labelling and the applicable destination requirements.
- Request relevant product information, specifications and supporting evidence through the company contact.
- Confirm storage, transport, traceability, complaints and safety-reporting responsibilities before any agreement.
The public catalogue extends beyond the initial planned facility modules. A listing does not mean that the dosage form is installed, qualified or licensed at Boten.
04 · External sources
Sources and further reading
External sources are provided for reference. Their authors do not endorse Luang Pharma, and another product’s authorisation does not transfer to this portfolio record. Source availability and wording can change.
Professional enquiries
Request product-specific evidence for LP-099.
State the exact presentation, organisation, destination and evidence needed. This public record is not an offer of supply.